Finally – after many false dawns – an effective new drug for Alzheimer’s is on the horizon. In early May, US scientists announced that the drug donanemab delays the worsening of symptoms by 35 per cent. Half the patients on the trial found their mental decline was halted for more than a year.
The Alzheimer’s Society went as far as describing the results as “the beginning of the end for Alzheimer’s disease”.
